Imatinib (STI-571, Gleevec; Novartis, Basel, Switzerland) is an adenosine-5 0 -triphosphate (ATP)-competitive tyrosine kinase inhibitor that is highly effective in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. This compound potently inhibits Bcr-Abl, the fusion protein that causes the onset of Philadelphia chromosome-positive chronic myeloid leukemia, and it also inhibits the receptor tyrosine Abbreviation: ALL, acute lymphoblastic leukemia. a Odds ratio is estimated using logistic regression comparing allele frequencies or genotype frequencies between ALL cases and controls. Controls for whites included individuals as previously described; 5 controls for blacks included 112 subjects as described in the text.
Letters to the Editor kinases c-KIT and platelet-derived growth factor receptor that have a role in gastrointestinal stromal tumors. Dasatinib (BMS-354825, Sprycel; Bristol-Meyers Squibb, New York, NY, USA) is an ATP-competitor that is structurally unrelated to imatinib and has been approved for the treatment of imatinibresistant chronic myeloid leukemia. Dasatinib has greater potency against Bcr-Abl and is effective against various imatinib-resistant Bcr-Abl mutants. However, it is also less specific and its range of targets includes the family of Src kinases, whose members have important roles in the growth and differentiation of various cell types. Both imatinib and dasatinib have been shown to suppress T-cell functions, [1] [2] [3] [4] [5] although the reasons for this are not fully established. The intracellular tyrosine kinase Lck is essential for the development and activation of T-cells and previous studies have shown that purified recombinant Lck can be inhibited by dasatinib and imatinib. 5, 6 Moreover, a large-scale kinome screen on recombinant kinase domains showed that imatinib binds to Lck, but not to the related Fyn and Src kinases. 7 As data obtained with purified proteins do not always translate to in vivo conditions, we set out to validate the selectivity profile of imatinib and dasatinib in a cellular context. We also aimed to obtain novel insights into the T-cell suppressive activities of these drugs and established that dasatinib inhibits T-cell function at clinically relevant concentrations, primarily through inhibition of Lck.
To compare the effects of imatinib on cellular Lck and other Src kinases, COS-7 cells were transiently transfected with cDNAs for constitutively active Lck, Fyn or Src. These proteins are active because of a phenylalanine substitution at the inhibitory tyrosine (Y505 in Lck) in the regulatory tail, and their activity can be assayed by the phosphorylation of another tyrosine in the ATP-binding site (Y394 in Lck, Y420 in Fyn and Y416 in Src). Incubation of cells with 6.25 mM imatinib for 2 h resulted in a considerable reduction in Y394 phosphorylation of Lck (Figure 1a ). Calculated over three separate experiments, the IC50 of this Lck inhibition was 2.6 mM. In contrast, imatinib did not cause a reduction in the activating phosphorylations of Fyn and c-Src at concentrations as high as 50 mM (Figures 1b and c) . Thus, imatinib inhibits Lck, but not Fyn or Src, confirming the selectivity detected in the kinome screen. 7 Cells were also treated with dasatinib that strongly inhibited all three Src kinases as expected (Figures  1e-g ). Next, we determined whether imatinib and dasatinib bind to Lck directly, by making use of an Lck mutant with a substitution at the gatekeeper residue (T316) that would be expected to confer resistance to imatinib and dasatinib. Indeed, LckT316M/Y505F was not inhibited by imatinib (Figure 1d ) or dasatinib (Figure 1h ). To extend this finding, we investigated the effects of imatinib and dasatinib on the ubiquitination of Lck that is dependent on an active conformation of the kinase domain but not on kinase activity per se, as it also occurs for a kinase-deficient K273R/Y505F mutant. 8 Both imatinib and dasatinib prevented ubiquitination of LckY505F, but had no effect on LckY505F/T316 M (Figure 1i ). Together, these experiments show that imatinib and dasatinib bind to the ATP-binding site of Lck and freeze the kinase domain in an inactive conformation.
Although the T-cell suppressive effects of imatinib and dasatinib have been attributed to Lck inhibition, paradoxically this was concluded from observed reductions in the inhibitory phosphorylation of Lck at Y505, 1,3 which in fact indicates an enhanced Lck activity. To clarify the effect of these drugs on Lck in T cells, we measured the phosphorylation of Lck at Y394 instead. Phosphorylation at this residue overrides the inhibitory effects of Y505 phosphorylation and thus absolutely correlates with activation. For these experiments, primary human T cells were isolated from single-donor buffy coats obtained from Figure 1 Imatinib binds to and inhibits Lck, not Fyn and c-Src. (a-h). COS-7 cells transiently transfected with cDNA for LckY505F (a and e), FynY531F (b and f), SrcY527F (c and g) or LckT316M/Y505F (d and h) were incubated for 2 h with imatinib (a-d) or dasatinib (e-h). Anti-pY416Src antibody was used to detect active Lck (pY394), Fyn (pY420) and Src (pY416) in cell lysates. Anti-Lck, anti-Fyn and anti-Src were used to detect the total amount of these kinases. Experiments were performed at least three times. (i) COS-7 cells were transiently transfected with cDNA for HA-ubiquitin and either LckY505F or LckT316M/Y505F cDNA. Cells were either left untreated or treated with imatinib or dasatinib for 6 h. Lck immunoprecipitates were western blotted with anti-HA to detect ubiquitinated Lck (top) or with anti-Lck to detect total Lck (bottom).
the National Blood Service (Tooting, UK) and stimulated with plate-bound anti-CD3 and anti-CD28. Stimulation in the presence of dasatinib resulted in a dose-dependent decrease in the early T-cell activation markers CD69 and CD25 and a reduction in cell division (Supplementary Figures S1 A, B) . A virtually complete decrease of T-cell activation was achieved at 12.5 nM dasatinib, a concentration that lies well within that found in the blood of patients, which can reach 100 nM. This inhibition of T-cell activation at 12.5 nM dasatinib correlated with a strong inactivation of Lck, based on a substantial decrease in Y394 phosphorylation (Figure 2a) . Concomitantly, phosphorylation of the Lck substrate Zap-70 and, further downstream, activation of ERK1/2 were also severely affected (Figure 2a) . Imatinib also inhibited T-cell activation, similar to what has been previously reported, 2,3,5 although considerable variation between donors was observed. An B50% inhibition of T-cell activation events was observed most commonly at 25 mM imatinib (Supplementary Figures S1 C, D) . A partial inactivation of Lck and partial reductions in Zap-70 and ERK1/2 phosphorylation were also consistently observed at 25 mM imatinib (Figure 2b ). In summary, the decreases in Y394 phosphorylation of Lck unequivocally show that dasatinib, and to a lesser extent imatinib, inhibit Lck, which correlates with inhibition of T-cell activation. Human primary T cells were stimulated with PHA for 15 min in the presence or absence of dasatinib (a) and imatinib (b). The drugs were present 1 h before and during PHA stimulation. Lck was immunoprecipitated and western blotted for active (pY394) or total Lck. Cell lysates were western blotted for active (pY319) and total ZAP-70, and for active ERK1/2 (pERK1/2) and total ERK1. Experiments were performed twice. 
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Given the robust effects of dasatinib, we next asked whether Lck is its prime target during T-cell activation. To determine this, cDNAs for C-terminal green fluorescent protein (GFP) fusion proteins of Lck or the imatinib/dasatinib-resistant LckT316M were transfected into primary human T cells. Stimulation of cells with anti-CD3/CD28 showed that Lck-GFP and LckT316M-GFPpositive cells were indistinguishable from untransfected cells with regard to CD69 upregulation (Figures 3a, panels 3 and 4 ; in b as graph). The presence of dasatinib abolished CD69 upregulation of both untransfected and Lck-GFP-transfected cells ( Figures 3a, panel 5; b) . However, T cells transfected with LckT316M-GFP were resistant to inhibition by dasatinib (Figures  3a panel 6; b) . To analyze this resistance at the protein level, Lck-GFP and LckT316M-GFP-transfected cells were purified by fluorescence-activated cell sorting before activation in the presence or absence of dasatinib. Lck-GFP and LckT316M-GFP were present at similar levels as endogenous Lck, as shown by western blotting (Figure 3c , total Lck). However, dasatinib treatment reduced pY394 levels of endogenous Lck and Lck-GFP, but not of LckT316M-GFP (Figure 3c, pY394) . Concurrently, total tyrosine phosphorylation, which is dependent on Lck, was reduced by dasatinib in Lck-GFP þ , but not in LckT316M-GFP þ cells (Figure 3d) . Thus, these data show that an Lck mutant can render T cells resistant to inhibition by dasatinib, indicating that Lck is the major target of dasatinib in T cells.
In summary, our results show for the first time in a cellular assay that dasatinib and imatinib bind directly to Lck and that imatinib selectivity inhibits Lck among the Src kinases. Furthermore, we show conclusively using Y394 phosphorylation, that imatinib and dasatinib inhibit Lck during T-cell activation. Moreover, we show that Lck is the main target through which dasatinib inhibits T-cell activation at clinically relevant concentrations.
The inhibition of T-cell functions by imatinib occurred at relatively high concentrations (25 mM) that are not likely to be clinically relevant. Imatinib concentrations peak in the blood at 4-5 mM when a daily dose of 400 mg is taken, and at 7.5 mM when this dose is received twice per day. In accordance with this, patients treated with imatinib are not evidently immunosuppressed. Strikingly, Lck was inhibited at far lower imatinib concentrations in COS-7 cells (IC50: 2.6 mM, Figure 1 ) than in primary T cells. In contrast, dasatinib inhibited Lck in COS-7 and T cells at similar concentrations. These differences may be because of cell type-specific differences in the expression of the (human) organ cation transporter (hOCT1), a plasma membrane transporter that is required for the uptake of imatinib, but not of dasatinib. 9 The potent inhibition of T cells in vitro by dasatinib is consistent with a report that 12 out of 16 patients treated longterm with 140 mg daily of dasatinib developed infection complications, 10 although the contribution of T cells in this is not yet fully determined.
Lck is an attractive target for the selective suppression of T-cell responses, given its restricted expression profile and essential role in T-cell activation. Drugs that selectively inhibit Lck would benefit patients with inflammatory diseases or after organ transplantation, and are expected to have an improved safety profile over currently used immunosuppressive agents that also target nonlymphoid cells. The imatinib results illustrate that it is feasible to inhibit Lck without affecting the ubiquitously expressed Src and Fyn. The related compound Nilotinib may also share this property.
11 Our identification of Lck as a key target of dasatinib in T cells further emphasizes the fact that the selective targeting of Lck, without the need to inhibit Fyn or other kinases, provides an efficient way of T-cell suppression. The valuable knowledge generated from the long-term use of imatinib and dasatinib, both in the laboratory and the clinic, may further instruct the development of tyrosine kinase inhibitors with more specific immunoregulatory functions, including those that selectively inhibit Lck.
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The authors declare no conflict of interest. Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by a sustained increase in platelet count and long-term survival. The long-standing threshold platelet count to define thrombocytosis of 600 Â 10 9 /l was recently lowered to 450 Â 10 9 /l by the World Health Organization in the 2008 classification. Thromboses, acute myeloid leukemia (AML) or myelofibrosis are the main complications of ET. Life expectancy of ET patients is good, with median survival ranging from 13 to 22.3 years.
1-3 Consequently, long-term follow-up studies that focus on ET-related complications and/or survival of ET patients must be conducted to register a sufficient number of events to provide informative results and statistical analyses. Many studies on outcomes in ET have been published, including well-conducted large-scale studies. However, most were single-institution studies that focused on patients referred to hospitals, which does not necessarily reflect the course of ET in the general population. Indeed, in these studies, the median age at diagnosis was younger (50-57-years old) than usually noted for ET patients in population-based studies (67-73-years old). 4, 5 Moreover, long-term outcomes in ET patients from population-based studies, usually involving o100 patients, are rarely investigated. Finally, in these studies, survival was generally based on observed mortality, a good but incomplete representation of overall mortality: given the old age (465 years) of half of the patients at the time of diagnosis, more specific analyses such as relative mortality, that describes mortality directly associated with the disease, thus ruling out biases related to age or other illnesses, should be carried out.
Taking the above into account, we carried out a long-term (1980-2007) retrospective study on 311 ET patients (174 females and 137 males) registered in the Registry of Hematological Malignancies of the Cô te d'Or area, France, the world oldest registry specialized in hematology.
The median age at diagnosis of 68.4 years (range: 15.8-94.4 years), and the World Standardized Population incidence rate was 1.4 per 100 000 inhabitants per year. The median follow-up was 9.5 years (range: 0-28). In all, 86% had received cytoreductive drugs, mainly hydroxyurea or pipobroman, during the follow-up. Altogether, 70% had received anti-platelet drugs alone (14%) or associated with cytoreductive treatment. The JAK2-V617F mutation assay was carried out for 129 out of 311 patients; 91 out of 129 (70%) were positive.
In our study, 125 (40%) patients died during the 1980-2007 period, at a median age of 81 years, with a median of overall survival of 11 years. Relative survival was 93, 83 and 47% after 5, 10 and 20 years of evolution, respectively.
As a consequence of both older age at diagnosis and longer follow-up, the mortality rate was higher (40%) than in other reports (from 8 to 27%) [1] [2] [3] 6 which underlines the differences between population-based and single-center studies (Table 1) . Nevertheless, this high rate of mortality allowed us to better analyze survival on a sufficiently large number of events (n ¼ 125) compared with previous studies with a low number of deaths (ranging from 20 to 30). 1, 4 When relative survival was analyzed, that is focusing on deaths directly associated with the disease, mortality because of ET was low in the first 10 years of evolution, as survival was 83% at 10 years. However, it decreased to 47% after 20 years of follow-up, with a generally regular curve with no steep falls. The difference between median observed and relative survival (11 versus 19.5 years) underlines the need to carry out the appropriate analyses to study the effect of a single disease on mortality. Finally, contrary to previous results 7 but in accordance with population-based studies, 4,5 survival in ET patients was significantly lower than the expected survival of an age-and sex-matched control population, and the discrepancy was mainly observed after 10 years of evolution.
A history of thrombosis was associated with higher mortality, but only in univariate relative survival. In contrast, neither thrombocytosis 41000 Â 10 9 /l nor the presence of the JAK2-V617F mutation at diagnosis were significantly associated with poorer survival.
Three independent parameters were noted as prognostic factors for relative survival in multivariate analysis: age 460 years, a hemoglobin level below normal values and leukocytosis 411 Â 10 9 /l. Our study provides data showing that, in relative survival, age 460 years is still a risk factor of survival; in other words, there is excess mortality because of ET per se in people over 60 years compared with younger patients.
A hemoglobin level below normal values was noted in 54 patients at diagnosis and was associated with a poor prognosis. One could imagine that patients with low level of hemoglobin had a myelodysplastic syndrome or a prefibrotic stage of primary myelofibrosis that could have previously been misdiagnosed, as these disorders are associated with worse overall survival and frequently anemia. However, at diagnosis there were no signs of myelodysplastic feature or fibrosis at bone marrow examination, either in morphology or histology in these patients. On the other hand, data such as increased blasts in the bone marrow or cytogenetic abnormalities during evolution were sometimes missing, leading to a possible underestimation of myelofibrosis transformation.
In the same way, our results confirm that leukocytosis at the time of diagnosis is also associated with poorer survival; compared with the previous studies that reported a white blood cell count (WBC) of 15 Â 10 9 /l associated with a worse
